Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have agreed to take part by signing a consent form before any study activities begin.
- People for whom the decision to start taking oral semaglutide (a commercially available tablet) was already made by both the person and their doctor, based on standard prescribing guidelines, before joining this study.
- Men or women aged 18 or older at the time of signing the consent form.
- People who have been diagnosed with type 2 diabetes.
- People currently taking metformin, with or without certain other diabetes tablets (such as a DPP4 inhibitor or SGLT2 inhibitor), and with or without insulin.
- People who have had a blood sugar control test (HbA1c) result above 7.0% either within the 90 days before their first study visit, or taken at the time of their first study visit if that is standard local practice.
Who may not be able to join:
- People who have previously taken part in this same study.
- People who have taken part in any other clinical trial involving an experimental drug within the 30 days before enrolling in this study.
- People who have difficulty understanding or cooperating due to mental capacity, unwillingness, or language barriers.
- People who have used a GLP-1 receptor agonist medication (a type of diabetes treatment) within the 90 days before their first study visit.
- People who have been diagnosed with type 1 diabetes.
- Women who are known to be pregnant, currently breastfeeding, undergoing fertility treatment, or planning to become pregnant during the study period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.